Want to see GB:OBD full AI Analyst Report?
OBD Stock Chart & Stats
0.12 p
>-0.01 p(-7.20%)
At close: 4:00 PM EDT
0.12 p
>-0.01 p(-7.20%)
Day’s Range― - ―
52-Week Range0.08 p - 0.75 p
Previous CloseN/A
Volume1.24M
Average Volume (3M)21.87M
Market Cap
£4.72M
Enterprise Value7.45M
Total Cash (Recent Filing)£2.51M
Total Debt (Recent Filing)£4.28M
Price to Earnings (P/E)―
Beta-0.35
Next Earnings
Jan 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding4,290,911,000
10 Day Avg. Volume50,883,470
30 Day Avg. Volume21,870,725
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.90
Price to Sales (P/S)6.02
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£1.80M
Bulls Say, Bears Say
Bulls Say
Proprietary Epigenetics Platform (EpiSwitch)OBD's EpiSwitch platform is a durable competitive asset: proprietary chromatin-based biomarker technology supports differentiated tests and licensing. A platform approach enables repeated assay development, long-term IP value, and multi-use applications across diagnostics and pharma collaborations.
Diverse Monetization Pathways (tests, Licensing, Partnerships)Multiple revenue streams—per-test sales, licensing fees, and partner-funded R&D—provide structural flexibility and recurring-contract potential. This reduces single-channel dependency and supports scaling revenue as clinical adoption and pharma collaborations expand over months.
Sustained Revenue GrowthMaterial top-line growth indicates market traction for products or collaborations. Durable revenue expansion over multiple periods can justify ongoing investment in validation and commercialization, improving the odds of reaching positive operating leverage if cost structures are managed.
Bears Say
Persistent Unprofitability And Negative MarginsChronic negative margins undermine retained earnings and internal funding capacity. Continued losses limit reinvestment into commercialization and validation, increasing reliance on external capital and raising execution risk if profitability is not achieved within a sustained timeframe.
High Financial Leverage (debt-to-equity 4.58)A very high debt-to-equity ratio increases fixed obligations and refinancing risk. Heavy leverage constrains strategic flexibility, raises sensitivity to interest costs, and can force dilutive equity raises or distressed funding solutions if cash generation does not improve.
Weak And Deteriorating Cash FlowDeclining free cash flow and negative operating cash conversion reduce the company's ability to self-fund R&D, commercialization, and working capital. Persistent cash shortfalls increase dependency on debt/equity financing and elevate execution and dilution risks over the medium term.
Oxford BioDynamics News
OBD FAQ
What was Oxford BioDynamics PLC’s price range in the past 12 months?
Oxford BioDynamics PLC lowest share price was 0.08 p and its highest was 0.75 p in the past 12 months.
What is Oxford BioDynamics PLC’s market cap?
Oxford BioDynamics PLC’s market cap is £4.72M.
When is Oxford BioDynamics PLC’s upcoming earnings report date?
Oxford BioDynamics PLC’s upcoming earnings report date is Jan 26, 2027 which is in 172 days.
How were Oxford BioDynamics PLC’s earnings last quarter?
Oxford BioDynamics PLC released its earnings results on Jun 30, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Oxford BioDynamics PLC overvalued?
According to Wall Street analysts Oxford BioDynamics PLC’s price is currently Overvalued.
Does Oxford BioDynamics PLC pay dividends?
Oxford BioDynamics PLC does not currently pay dividends.
What is Oxford BioDynamics PLC’s EPS estimate?
Oxford BioDynamics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oxford BioDynamics PLC have?
Oxford BioDynamics PLC has 4,290,911,000 shares outstanding.
What happened to Oxford BioDynamics PLC’s price movement after its last earnings report?
Oxford BioDynamics PLC reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -33.333%.
Which hedge fund is a major shareholder of Oxford BioDynamics PLC?
Currently, no hedge funds are holding shares in GB:OBD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oxford BioDynamics PLC
Oxford BioDynamics Plc operates as a biotechnology firm that specializes in identifying and advancing biomarkers, primarily for the pharmaceutical and biotechnology sectors across global markets, including the United States. Its flagship offering is EpiSwitch, an exclusive technological platform employed for discovering, assessing, validating, and tracking epigenetic biomarkers, specifically referred to as chromosome conformation signatures. These are crucial for developing medical diagnostic kits, predicting disease onset, aiding in diagnosis, and informing therapeutic strategies. The company's key products encompass the EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic tool for forecasting patient responses to checkpoint inhibitor immunotherapy; the EpiSwitch CST (Covid Severity Test), a sophisticated blood test designed to predict the severity of COVID-19 in adults; and the EpiSwitch Explorer Array Kit, which enables high-resolution 3D genome analysis and novel biomarker discovery. Established in 2007, Oxford BioDynamics Plc maintains its headquarters in Oxford, United Kingdom.
Technical Analysis
IXICO plc
―
SkinBioTherapeutics
―
Fusion Antibodies Plc
―
Genflow Biosciences Plc
―
Aptamer Group Plc
―